Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of ObesityBenzinga • 04/06/22
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of ObesityGlobeNewsWire • 04/06/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rhythm Pharmaceuticals, Inc. - RYTMPRNewsWire • 03/26/22
Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care ConferenceGlobeNewsWire • 03/01/22
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/01/22
Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership TeamGlobeNewsWire • 02/23/22
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022GlobeNewsWire • 02/22/22
Rhythm Pharma's Highlights Interim Setmelanotide Data In Long Term Genetic Disorder TrialBenzinga • 02/16/22
Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16GlobeNewsWire • 02/08/22
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of ObesityGlobeNewsWire • 01/13/22
Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in ChinaGlobeNewsWire • 12/06/21
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström SyndromeGlobeNewsWire • 11/15/21
Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/02/21
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021GlobeNewsWire • 11/01/21
Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021GlobeNewsWire • 10/20/21
Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström SyndromesGlobeNewsWire • 10/14/21
Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing ProgramGlobeNewsWire • 10/14/21
Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE MeetingGlobeNewsWire • 09/22/21
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great BritainGlobeNewsWire • 09/21/21